Phase 3 Mastocytosis Clinical Trials
2 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–2 of 2 trials
Recruiting
Phase 2Phase 3
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Indolent Systemic MastocytosisSmoldering Systemic Mastocytosis
Blueprint Medicines Corporation534 enrolled64 locationsNCT04910685
Completed
Phase 2Phase 3
A randomized, placebo-controlled, double blind, parallel design study of Xolair (omalizumab) for the management of treatment-resistant systemic and cutaneous mastocytosis.
Systemic mastocytosisMastocytosis in the skin
Novartis Pharmaceuticals30 enrolled1 locationACTRN12613001096741